Baxter Intl Inc Stock Price, News & Analysis

Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.17 per share of common stock, payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share. This new quarterly dividend rate is set in anticipation of the Kidney Care business segment divestiture to Carlyle, expected to close in late 2024 or early 2025. The dividend targets a payout ratio of approximately 25% of adjusted net income, aligning with peer companies. Baxter maintains its 93-year history of consistent dividend payments while balancing business reinvestment with shareholder returns.

Baxter (BAX) reported Q3 2024 total sales of $3.85 billion, with continuing operations sales of $2.70 billion increasing 4% on both reported and constant currency basis. The company achieved total U.S. GAAP diluted EPS of $0.27 and adjusted EPS of $0.80, exceeding previous guidance. Hurricane Helene significantly impacted the North Cove facility, though production has restarted on the highest-throughput IV solutions line. The company announced the pending sale of its Kidney Care business to Carlyle for $3.80 billion, expected to close in late 2024 or early 2025. Due to hurricane impact, Baxter adjusted its full-year 2024 outlook, expecting total company sales growth of 1-2% and adjusted EPS of $2.90-$2.94.

Baxter International (NYSE:BAX) announced its participation in the upcoming UBS Global Healthcare Conference. Chief Financial Officer Joel Grade will deliver a presentation on Wednesday, November 13, 2024, at 1:15 p.m. Pacific Time. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 12, 2025.

Baxter International Inc. (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. Interested participants can pre-register for the call through a provided link to receive call information. The conference call will also be webcast and accessible via Baxter's website at www.baxter.com. Baxter has noted that the call will be recorded and is copyrighted material, prohibiting unauthorized recording or rebroadcasting without the company's permission.

Baxter International Inc. (NYSE:BAX) has provided an update on the impact of Hurricane Helene on its North Cove facility in Marion, N.C. The facility is currently closed for production due to flooding, and the company is working closely with various government agencies to assess the damage and resume operations. Key points:

1. Baxter is implementing measures to minimize supply disruptions, including managing inventory and using a protective allocation process.
2. The company will leverage its global manufacturing network to mitigate potential supply impacts.
3. The Baxter International Foundation has committed $1.5 million in donations for recovery efforts and is matching employee donations 2:1.
4. Baxter anticipates a negative impact on its financial results due to the disruption and plans to provide an update in its third quarter earnings announcement.

Baxter International Inc. (NYSE:BAX) has launched The Vest Advanced Pulmonary Experience (APX) System, its next-generation airway clearance system, at the North American Cystic Fibrosis Conference. This system, designed for adults and children with certain chronic lung conditions and retained secretions, features enhanced comfort and patient-centered improvements based on clinician and patient input.

Key features include:

• A streamlined, lightweight garment with wicking fabric and Velcro closure
• New garment colors and designs for adults and children
• User-friendly touch screen navigation
• Smaller and lighter control unit with carrying case
• Optional CARE Connex Program for ongoing support

The Vest APX System uses High Frequency Chest Wall Oscillation (HFCWO) technology to help dislodge and mobilize mucus in the lungs. Baxter received FDA 510(k) clearance for the system earlier this year, and it will be available to order this fall.

Baxter International Inc. (NYSE:BAX), a global medtech leader, has appointed Jeffrey (Jay) A. Craig to its board of directors. Craig, former executive chair and CEO of Meritor , will serve on Baxter's Audit Committee. His appointment is effective immediately, bringing the total number of directors to 12. Baxter's chair, president and CEO, José (Joe) E. Almeida, expressed excitement about Craig's addition, highlighting his broad-based business leadership and operational expertise as a former CEO, CFO, COO, and public company auditor. This appointment is expected to complement the current board's expertise with Craig's deep financial experience and public company board background.

Baxter International (NYSE:BAX), a global medtech leader, is set to participate in the 2024 Wells Fargo Healthcare Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Thursday, September 5, 2024, at 1:30 p.m. Eastern Time.

Investors and interested parties can access the live webcast of Baxter's presentation through the company's official website, www.baxter.com. For those unable to attend the live event, a replay of the presentation will be available on the same platform until Tuesday, March 4, 2025. This presentation offers an opportunity for stakeholders to gain insights into Baxter's current operations, financial performance, and future strategies.

Baxter International Inc. (NYSE:BAX) has announced a definitive agreement to sell its Kidney Care segment, to be named Vantive, to Carlyle for $3.8 billion. This strategic move is part of Baxter's ongoing business transformation aimed at enhancing performance and creating value for stakeholders. The transaction is expected to close in late 2024 or early 2025, subject to regulatory approvals and other conditions.

Key points:

• Baxter will receive approximately $3.5 billion in cash, with estimated net after-tax proceeds of $3 billion
• Proceeds will be used to reduce Baxter's debt
• Vantive, a leader in global kidney care, had 2023 revenues of $4.5 billion
• Post-divestiture, Baxter targets 4-5% annual operational sales growth and an adjusted operating margin of about 16.5% for 2025